Download PDFPDF
Anti-tumour necrosis factor agents and lipid profile: a class effect?
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    The lipids after one year therapy with infliximab and etanercept in woman with rheumatoid arthritis
    • Maciej Lewicki, assistant
    • Other Contributors:
      • ,Przemyslaw Kotyla, Sebastian Giebel, Eugene J Kucharz

    Dear Editor,

    We read with the great interest the paper by Garces et al. Anti-tumour necrosis factor agents and lipid profile: a class effect? [1] In this study the investigators showed the different effect on lipid profile between infliximab and etanercept in patient with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). We would like to present the similar study in RA patients treate...

    Show More
    Conflict of Interest:
    None declared.